An interventional study of Video capsule endoscopy in Lynch Syndrome, Lynch Syndrome I and Lynch Syndrome II, sponsored by San Raffaele University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by San Raffaele University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy — 9 open to participants now, 9 under way, none of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · Italy.
Among the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy, this one is the only one that started in 2018, is one of 2 with no phase, and was the 2nd registered.
147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →9 of the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy are open now. Recruiting first, the newest first:
Vividion Therapeutics, Inc. · Sites in Italy, United States, Argentina and 19 more countries
Ages 18+
San Raffaele University · Sites in Italy
Ages 18+ · Healthy volunteers
San Raffaele University · Sites in Italy, United States
Ages 18+
Associazione Italiana per lo Studio del Pancreas · Sites in Italy
Ages 18–80
UNICANCER · Sites in Italy, Croatia, Czechia and 6 more countries
Ages 35–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2018.
This study's planned enrollment of 100 is below the median of 200 across 77 interventional studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Median enrollment 140 across the 3 interventional studies, 300 across the 7 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 8 most frequent:
San Raffaele University is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
San Raffaele University has 3 studies filed under Colorectal Neoplasms, Hereditary Nonpolyposis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2/Epcam, MSH6, or PMS2. These pathogenic variants confer a higher risk of developing colorectal and other cancers, including small bowel cancer. The risk of developing a small bowel adenocarcinoma is about 100 times higher compared to individuals without Lynch syndrome, and the lifetime risk of small bowel cancer is estimated at 4,2%.
The diagnosis of a small bowel cancer depends on videocapsule endoscopy (VCE). This device is swalled so that it can record images of the small bowel, which are then stored on a wearable device for about 8 hours. The capsule is then expelled in the feces while the images are transferred to a computer to be analysed. To date, there is conflicting evidence on the efficacy of small bowel cancer screening with VCE
Rationale: this registry study will collect prospective data from patients with LS undergoing VCE
Aim: evaluate the incidence of neoplastic and pre-neoplastic lesions in patients with LS during a VCE-based small bowel cancer screening study
Design: this is a multicentric, observational study that analyzes data from diagnostic techniques already approved. Patients will not undergo diagnostic procedures beyond what would be recommended by clinical practice.
Background Lynch syndrome (LS) is caused by a pathogenic germline defect in one of the mismatch repair genes (MMR), namely MLH1, MSH2/Epcam, MSH6, or PMS2. Such pathogenic defects confer a higher risk of developing not only colorectal cancer but also small bowel cancer (SBC). Patients with LS have a lifetime risk of SMB of 4.2%, with a relative risk of >100, compared to the general population. Moreover, patients with LS may develop SBC at a younger age, compared to SBC in individuals without LS.
The diagnostic standard for SBC is video capsule endoscopy (VCE). This consists in swallowing a pill with a camera inside. The VCE will record the images through the gastrointestinal tract and send them via Bluetooth to a wearable device for roughly 8 hours The capsule is then expelled with feces while the images are stored in a computer for later revision. Today, the data on the efficacy of a screening program for SBC in patients with LS is controversial.
Rationale This register study will collect prospective data on the VCEs done on patients with LS
Objective To estimate the incidence of neoplasia and preneoplastic lesions of the small bowel in patients with LS via VCE
Design Multicentric observational study with the use of approved diagnostic devices. It will not modify the current standard of care. The study design will not mandate obligatory studies of further procedures besides those that are clinically approved.
Population At least 10 subjects/year by each center (400 patients by study completion)
Controindications to VCE
Risks of VCE VCE retention is the most dreaded adverse events. The risk may vary between 1.5 and 21%.
Allergic reactions may be possible due to the use of sticky electrodes on the skin.
Study duration 10 years from January 2016.
Confounders To date, not known.
Data management All results will remain confidential. Clinical data may become available at scientific meetings or in published articles, but patient anonymity will always be maintained
Statistics The incidence of neoplastic and preneoplastic lesions of the subjects included in the study will be estimated. The sample size was established on the basis of feasibility (10 subjects enrolled each year for each center in 10 years = 400 patients in total). The expected incidence of small bowel injury is approximately 5%. With 400 subjects it is possible to estimate the incidence with an accuracy of 2% estimated with a 95% confidence interval.
Descriptive statistical variables (mean, standard deviation, median, etc.) will be evaluated on the collected data.
Any relationships between these variables will be evaluated using inferential statistics (t-test, chi-squared, logistic regression analysis, multivariate analysis, etc.). Any relationship with a p-value less than 0.05 will be considered significant.
Ethics The investigators declare that the study will be conducted in accordance with the ethical principles deriving from the Declaration of Helsinki and the current legislation on Observational Studies.
Informed consent. All subjects will be informed of the purpose of the study, of the confidentiality of the personal data, and of the fact that this data may be subject to review, for study-related reasons, by authorized person other than the physician.
It will be emphasized that participation is entirely voluntary and that the patient can refuse further participation in the protocol at any time without affecting the patient's subsequent care. Informed consent will be obtained for all subjects included in the study prior to their inclusion in the present study, in accordance with national and local regulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Video capsule endoscopy every 2 years
Device: Video capsule endoscopy
Video capsule endoscopy every 2 years
Small bowel adenocarcinoma
Annual incidence
Time frame: 10 years
Small bowel adenoma
Annual incidence
Time frame: 10 years
Plan to share: Undecided
Started Nov 2018 (actual). Primary completion is estimated for Dec 2028, 121 months after the start.
Of 37 interventional studies with no phase under Colorectal Neoplasms, Hereditary Nonpolyposis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 86. This study's planned 121 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Colorectal Neoplasms, Hereditary Nonpolyposis →
San Raffaele University